Improved Clinical Sensitivity of a Reflexive Algorithm to Minimize False-Negative Test Results by a Urine Benzodiazepine Immunoassay Screen
- 1 January 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 2 (4) , 555-563
Abstract
Background: Urine drug testing is an essential component of treating patients for chronic pain and/or anxiety and is used to monitor compliance during treatment. A common algorithm is to use an immunoassay as a urine drug screen (UDS), followed by mass spectrometry to confirm all presumptive positive samples. Many UDSs, however, have significant limitations, and false-negative test results can be common due to lack of antibody specificity. Methods: Urine samples were screened by a benzodiazepine immunoassay followed by confirmatory testing using LC-MS/MS to determine an initial false-negative test rate for the screen. Attempts to improve the false-negative test rate included hydrolysis before screening and optimization of the absorbance cutoff required for a positive result. Results: Hydrolysis corrected 41% of false-negative test results in samples containing parent benzodiazepines and/or metabolites but had no effect on samples containing only clonazepam. Of the confirmed false-negative test results, 85% (17 of 20) demonstrated absorbance values between 20 and 100, with 100 being the cutoff for a positive result. Implementing an optimized absorbance cutoff of 20, rather than 100, for a reflexive confirmation testing algorithm decreases the false-negative test rate of detecting benzodiazepine from 47% to 2%. Conclusions: Hydrolyzing samples before the benzodiazepine screen provided a modest improvement in the false-negative test rate; however, the screen still missed samples containing clonazepam. Optimization of the absorbance cutoff to reflex samples to LC-MS/MS markedly improved the false-negative test rate for all benzodiazepines.Keywords
This publication has 14 references indexed in Scilit:
- Limitations of EMIT Benzodiazepine Immunoassay for Monitoring Compliance of Patients With Benzodiazepine Therapy Even After Hydrolyzing Glucuronide Metabolites in Urine to Increase Cross-ReactivityTherapeutic Drug Monitoring, 2015
- Optimizing Urine Drug Testing for Monitoring Medication Compliance in Pain ManagementPain Medicine, 2013
- Demystifying Analytical Approaches for Urine Drug Testing to Evaluate Medication Adherence in Chronic Pain ManagementJournal of Pain & Palliative Care Pharmacotherapy, 2013
- Cross-reactivities and structure–reactivity relationships of six benzodiazepines to EMIT® immunoassayJournal of Pharmaceutical and Biomedical Analysis, 2013
- Comparison of Immunoassay Screening Tests and LC-MS-MS for Urine Detection of Benzodiazepines and Their Metabolites: Results of a National Proficiency TestJournal of Analytical Toxicology, 2013
- Benzodiazepines and alcohol are associated with cases of fatal buprenorphine poisoningEuropean Journal of Clinical Pharmacology, 2011
- Urine Benzodiazepine Screening using Roche Online(R) KIMS Immunoassay with -Glucuronidase Hydrolysis and Confirmation by Gas Chromatography-Mass SpectrometryJournal of Analytical Toxicology, 2005
- A Survey of Drugs of Abuse Testing by Clinical Laboratories in the United KingdomAnnals of Clinical Biochemistry: International Journal of Laboratory Medicine, 1990
- Urine Testing in the Detection of Drugs of AbuseArchives of internal medicine (1960), 1988
- Clonazepam acetylation in fast and slow acetylatorsClinical Pharmacology & Therapeutics, 1981